Cabaletta Bio 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Cartesian Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Arcutis Biotherapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Black Diamond Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Prelude Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Foghorn Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Chronic Kidney Disease Indication Strategy Report 2026: SGLT2, MR, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Atopic Dermatitis Indication Strategy Report 2026: IL-4Rα, IL-13, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Lupus Nephritis Indication Strategy Report 2026: BAFF, CD20, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

A 2026 multiple myeloma strategy report covering disease burden, BCMA and GPRC5D biology, clinical competition, deal activity and portfolio positioning.

Alzheimer's Disease Indication Strategy Report 2026: Amyloid-β, Tau, Trials and $2.2B Deal uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

A 2026 NSCLC indication strategy report covering epidemiology, EGFR and KRAS biology, Phase 3 competition, deal activity and R&D positioning.